Evidence map›Paper›PMID 28565859›Full record

ArticleExperimental and therapeutic medicine2017

Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.

Ruifang Li, Lin Zhang, Huiru Zhang, Yanjie Yi, Le Wang, Liang Chen, Lan Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022
    Review
  4. Inhibition ofBioengineered · 2022
    Article
  5. Article
  6. Review
  7. Bioactive Peptides Against Fungal Biofilms.Frontiers in microbiology · 2019
    Review
  8. Methodologies forMicrobial cell (Graz, Austria) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ruifang LiCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Lin ZhangCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Huiru ZhangCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Yanjie YiCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Le WangCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Liang ChenCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Lan ZhangCollege of Biological Engineering, Henan University of Technology, Zhengzhou, Henan 450001, P.R. China.
Henan University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive fungal infections threat the life of immunocompromised patients. Chromogranin A N-46 (CGA-N46), corresponding to the 31st to 76th amino acids of the N-terminus of human chromogranin A, is an antifungal peptide. In order to elucidate the antifungal effects of CGA-N46

Indexed as

antifungal peptideCGA-N46chromogranin Aimmunocompromised Candida krusei-infected mice modelimmuno-modulatory effectprotective effect

Identifiers

PMID28565859
PMCPMC5443283
OpenAlexW2598993632

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.